Dynamics of ratios of prolactin and hormones of the hypothalamic-pituitary thyroid axis in patients with schizophrenia

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

In 70 examined patients – 34 with the first psychotic episode (FPE) and 36 with chronic schizophrenia (CS), a dynamic study of the parameters of prolactin (PRL), thyroid-stimulating hormone (TSH) and thyroxine (T4) free during olanzapine therapy was carried out. 52.9% of patients with FPE had background hyperprolactinemia (HP) with mean values of 971.1 ± 420 mIU/l, and in the group with CS, in 50% of patients (mean prolactin values were 1131 ± 845.4 mIU/l). In 11.8% of patients with FPE and in 16.6% of patients with CS, the level of T4 free was below the standard values (mean values: 7.5 ± 0.3 pmol/l and 8.0 ± 0.8 pmol/l, respectively). TSH parameters in patients with FPE were within the reference values. Elevated background levels of TSH in patients with CS were observed in 11.1% of cases (4.8 ± 0.7 mIU/ml). By 6–8 weeks, an increase in mean PRL values was observed in all patients. Fluctuations in thyroid hormone levels by the end of therapy were insignificant. Four variants of dynamic changes in PRL and hypothalamic-pituitary-thyroid (HPT) axis hormones in patients during olanzapine therapy were identified. The relationship between PRL and thyroid hormones is discussed. The data obtained dictate the need to study the characteristics of the ratio of the levels of these hormones before the start of antipsychotic therapy (AT) in order to detect hypothyroidism and HP early, as well as to prevent the development of these hormonal dysfunctions in the process of AT and confirm the need to assess the levels of PRL and HPT-axis hormones in patients with FPE and CS before the start of the appointment of AT.

Full Text

Restricted Access

About the authors

L. N. Gorobets

Moscow Research Institute of Psychiatry – branch of the Federal State Budgetary Institution “Serbsky National Medical Research Centre for Psychiatry and Narcology” of the Ministry of Health of Russia

Author for correspondence.
Email: gorobetsln@mail.ru
Russian Federation, Moscow

A. V. Litvinov

Moscow Research Institute of Psychiatry – branch of the Federal State Budgetary Institution “Serbsky National Medical Research Centre for Psychiatry and Narcology” of the Ministry of Health of Russia

Email: gorobetsln@mail.ru
Russian Federation, Moscow

V. S. Bulanov

Moscow Research Institute of Psychiatry – branch of the Federal State Budgetary Institution “Serbsky National Medical esearch Centre for Psychiatry and Narcology” of the Ministry of Health of Russia

Email: gorobetsln@mail.ru
Russian Federation, Moscow

References

  1. Abi-Dargham A. // Eur. Psychiatry. 2002. 17 (Suppl. 4). P. 341–347.
  2. Crow T.J. // Psychopharmacol. Bull. 1982. № 18. P. 22–29.
  3. Grace A.A. // Neurosci. 1991. № 4. P. 1–24.
  4. Лавин Л. Эндокринология. М., 1999. 1128 с.
  5. Угрюмов М.В. Механизмы нейроэндокринной регуляции. М.: Наука, 1999. 299 с.
  6. Горобец Л.Н., Матросова М.И. // Журнал неврологии и психиатрии им. С.С. Корсакова. 2010. Т. 110. № 5. С. 17–22.
  7. Горобец Л.Н., Матросова М.И. // Уральский журнал психиатрии, наркологии и психотерапии. Екатеринбург. 2013. Т. 1. Вып. 3. С. 29–36.
  8. Aston J., Rechsteiner E., Bull N., Borgwandt S., Gschwandtner U. // Progress in Neuro-Psychopharm. & Biol. Psychiatry. 2010. № 14. P. 1342–1344.
  9. Reichelt K.L., Gardner M.L.G. // Open Journal of Psychiatry. 2012. № 2. Р. 12–20.
  10. Горобец Л.Н. Нейроэндокринные дисфункции и нейролептическая терапия. М.: Медпрактика-М, 2007. 312 с.
  11. Горобец Л.Н., Литвинов А.В. // Российский медико-биологический вестник имени академика И.П. Павлова. 2008. № 3. С. 71–78.
  12. Barbero J.D., Gutiérrez-Zotes A., Montalvo I., Creus M., Cabezas A., Sole M., Algora M.J., Garcia-Pares G., Vilella E., Labad J. // Schizophr. Res. 2015. Aug. 166(1–3). Р. 37–42.
  13. Fryar-Williams S., Strobel J.E. // Open Journal of Psychiatry. 2015. № 5. Р. 78–112.
  14. Garner B., Pariante C.M., Wood S.J., Velakoulis D., Phillips L., Soulsby B. // Biol. Psychiatry. 2005. № 58. Р. 417–423.
  15. Segal M., Avital A., Berstein S. // Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007. Mar. 30–31(2). P. 378–382.
  16. Shankar G.S., Yuan C. // Autacoids. 2013. № 2 (article 102).
  17. Telo S., Bilgic S., Karabulut N. // West Indian Med. J. 2016. Mar. 15. № 65(2). Р. 312–315.
  18. Themeli Y., Aliko I., Hashorva A. // European Psychiatry. 2011. № 26. Vol. 1. Article 1515. P. S90.
  19. Горобец Л.Н. // Российский психиатрический журнал. 2006. № 6. С. 68–75.
  20. Evers S.S., van Vliet A., van Vugt B., Scheurink A.J., van Dijk G.A. // Psychoneuroendocrinology. 2016. Apr. № 66. Р. 101–110.
  21. Haddad P.M., Wieck A. // Drugs. 2004. № 64. Р. 2291–314.
  22. Jakovljevic M., Pivac N., Mihaljevic-Peles A. // Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007. Mar 30. 31(2). P. 399–402.
  23. Seddigh R.,Azarnik S., Keshavarz-Akhlaghi A. // Case Rep. Psychiatry. 2015. ID678040. P. 1–4.
  24. Камкин А.Г., Каменский А.А. Фундаментальная и клиническая физиология: учебник для студ. высш. учебн. заведений. М.: Академия, 2004. 1072 с.
  25. Татарчук Т.Ф., Ефименко О.А. // Международный эндокринологический журнал. 2010. № 3(27).
  26. Горобец Л.Н. // Сибирский вестник психиатрии и наркологии. 2008. № 3(50). С. 88–93.
  27. Baumgartner A., Pietzcker A., Gaebel W. // Schizophrenia Research. 2000. № 44(3). Р. 233–243.
  28. Ichioka S., Terao T., Hoaki N., Matsushita T., Hoaki T. // Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2012. № 39(1). Р. 170–174.
  29. Krysiak R., Szkróbka W., OkopieńB. // J. Clin. Pharmacol. 2017. Dec. 18. Vol. 58. Iss. 5. P. 586–592.
  30. Santos N.C., Costa P., Ruano D., Macedo A., Soares M.J., Valente J., Pereira A.T., Azevedo M.H., Palha J.A. // Journal of Thyroid Research. 2012. Р. 11–15.
  31. Мосолов С.Н. Шкалы психометрической оценки симптоматики шизофрении и концепция негативных и позитивных расстройств. М.: Новый цвет, 2001.
  32. Горобец Л.Н., Литвинов А.В., Буланов В.С., Узбекова Д.Г. // Социальная и клиническая психиатрия. 2019. № 2. С. 1–5.
  33. Garcia-Rizo C., Fernandez-Egea E., Oliveira C., Justicia A., Parellada E., Bernardo M., Kirkpatrick B. // Schizophr. Res. 2012. № 134(1). Р. 16–19.
  34. Jose J., Nandeesha H., Kattimani S., Meiyappan K., Sarkar S., Sivasankar D. // Clin. Chim. Acta. 2015. Apr. 15. № 444. Р. 78–80.
  35. Haddad P.M., Wieck A. // 2004. № 64. Р. 2291–314.
  36. Riecher-Rössler A., Rybakowski J.K., Pflueger M.O., Beyrau R., Kahn R.S., Malik P., Fleischhacker W.W. and the EUFEST Study Group // Psychological Medicine. 2013. № 43. Р. 2571–2582.
  37. Segal M., Avital A., Rojas M., Hausvater N., Sandbank S., Liba D., Moguillansky L., Tal I., Weizman A. // Psychiatry Res. 2004. Jul. 15.127 (3). P. 227–235.
  38. Bauer M., Whybrow P.C. // J. Endocrinol. Invest. 2021. Nov. № 44(11). Р. 2341–2347.
  39. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., López-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Grobbee D.E.; EUFEST study group // Lancet. 2008. № 371. Р. 1085–1097.
  40. MacMaster F.P., El-Sheikh R., Upadhyaya A.R. // Schizophr. Res. 2007. May. № 92(1–3). P. 207–210.
  41. Mondelli V., Dazzan P., Gabilondo A., Tournikioti K., Walshe M., Marshall N. // Psychoneuroendocrinology. 2008. № 33. Р.1004–1012.
  42. Grattan D.R., Kokay I.C. // J. Neuroendocrinol. 2008. № 20. Р. 752–763.
  43. Crocker A.D., Overstreet D.H. // Psychopharmacology. 1984. № 82(1–2). Р. 102–106.
  44. Nakazawa K., Zsiros V., Jiang Z., Nakao K., Kolata S., Zhang S., Belforte J.E. // Neuro-pharmacology. 2012. № 62(3). Р. 1574–1583.
  45. Schmidt M.J., Mirnics K. // Neuropsychopharmacology. 2015. № 40(1). Р. 190–206.
  46. Wiens S.C, Trudeau V.L. // Comparative Biochemistry and Physiology. 2006. № 144(3). Р. 332–344.
  47. Maino F., Cantara S., Forleo R. // Expert Review of Endocrinology & Metabolism. 2018. Vol. 13. No. 5. Р. 273–77.
  48. Marsan E.S., Bayse C.A. // Molecules. 2020. Vol. 25. No. 6. Р. 1328.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Frequency of occurrence of the selected subgroups of patients.

Download (64KB)
Indexing metadata

Copyright (c) 2024 Russian Academy of Sciences